Clinical Trial Update: A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study assessing Alpharadin in combination with Docetaxel in patients with bone metastases from castration-resistant prostate cancer has completed. Res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Alpharadin (Radium-223 chloride)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Bayer | Conditions: Bone Metastases, Castration-Resistant Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-11-09